Sexual Health Partnering 2010 to 2016 provides the full collection of
Sexual Health disease deals signed between the world's pharmaceutical
and biotechnology companies since 2010. Most of the deals included
within the report occur when a licensee obtains a right or an option
right to license a licensor's product or technology. More often these
days these deals tend to be multi-component including both a
collaborative R&D and a commercialization of outcomes element. The
report takes readers through the comprehensive Sexual Health disease
deal trends, key players and top deal values allowing the understanding
of how, why and under what terms companies are currently entering Sexual
Health deals. The report presents financial deal terms values for
Sexual Health deals, where available listing by overall headline values,
upfront payments, milestones and royalties enabling readers to analyse
and benchmark the value of current deals. Global Sexual Health
Partnering 2010 to 2016 includes:
Trends in Sexual Health dealmaking in the biopharma industry since 2010
Analysis of Sexual Health deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Sexual Health deal contract documents
Comprehensive access to over 3500 Sexual Health deal records
The leading Sexual Health deals by value since 2010
Most active Sexual Health dealmakers since 2010
In Global Sexual Health Partnering 2010 to 2016, available deals and contracts are listed by:
Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Next
« Prev Post
« Prev Post
Previous
Next Post »
Next Post »
Subscribe to:
Post Comments (Atom)
Show Conversion Code Hide Conversion Code Show Emoticon Hide Emoticon